Type I interferon signaling in hematopoietic cells is required for survival in mouse polymicrobial sepsis by regulating CXCL10

Journal of Experimental Medicine

Volumn 207, Issue 2, 2010, Pages 319-326

  Kelly Scumpia, Kindra M ^a   Scumpia, Philip O ^a   Delano, Matthew J ^a   Weinstein, Jason S ^a   Cuenca, Alex G ^a   Wynn, James L ^b   Moldawer, Lyle L ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR; ALPHA INTERFERON; BETA INTERFERON; ENDOTOXIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON; CXCL10 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; EXPERIMENTAL MODEL; FLOW CYTOMETRY; IMMUNE RESPONSE; INFLAMMATION; MORTALITY; MOUSE; NEUTROPHIL; NONHUMAN; PERITONITIS; PHAGOCYTOSIS; PRIORITY JOURNAL; SEPSIS; SINGLE DRUG DOSE; SURVIVAL; ADAPTIVE IMMUNITY; ANIMAL; CECUM; DEFICIENCY; DISEASE MODEL; HEMATOPOIESIS; HUMAN; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ADAPTIVE IMMUNITY; ANIMALS; CECUM; CHEMOKINE CXCL10; DISEASE MODELS, ANIMAL; HEMATOPOIESIS; HUMANS; INTERFERON TYPE I; MICE; NEUTROPHIL INFILTRATION; NEUTROPHILS; PHAGOCYTOSIS; RECEPTOR, INTERFERON ALPHA-BETA; SEPSIS; SIGNAL TRANSDUCTION;

EID: 77149144182     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20091959     Document Type: Article

References (35)

1. Blanco, P., A.K. Palucka, M. Gill, V. Pascual, and J. Banchereau. 2001. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science. 294:1540-1543. doi:10.1126/science.1064890
2. Bone, R.C. 1996. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit. Care Med. 24:1125-1128. doi:10.1097/00003246-199607000-00010
3. Danikas, D.D., M. Karakantza, G.L. Theodorou, G.C. Sakellaropoulos, and C.A. Gogos. 2008. Prognostic value of phagocytic activity of neutrophils and monocytes in sepsis. Correlation to CD64 and CD14 antigen expression. Clin. Exp. Immunol. 154:87-97. doi:10.1111/j.1365-2249.2008.03737.x
4. + population induces T cell suppression and Th2 polarization in sepsis. J. Exp. Med. 204:1463-1474. doi:10.1084/jem.20062602
5. Döcke, W.D., F. Randow, U. Syrbe, D. Krausch, K. Asadullah, P. Reinke, H.D. Volk, and W. Kox. 1997. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat. Med. 3:678-681. doi:10.1038/nm0697-678
6. Eskandari, M.K., G. Bolgos, C. Miller, D.T. Nguyen, L.E. DeForge, and D.G. Remick. 1992. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J. Immunol. 148:2724-2730.
7. Hoebe, K., and B. Beutler. 2004. LPS, dsRNA and the interferon bridge to adaptive immune responses: Trif, Tram, and other TIR adaptor proteins. J. Endotoxin Res. 10:130-136.
8. Hotchkiss, R.S., and I.E. Karl. 2003. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348:138-150. doi:10.1056/NEJMra021333
9. Huys, L., F. Van Hauwermeiren, L. Dejager, E. Dejonckheere, S. Lienenklaus, S. Weiss, G. Leclercq, and C. Libert. 2009. Type I interferon drives tumor necrosis factor - induced lethal shock. J. Exp. Med. 206:1873-1882. doi:10.1084/jem.20090213
10. Isaacs, A., and D.C. Burke. 1959. Viral interference and interferon. Br. Med. Bull. 15:185-188.
11. Kaufmann, I., A. Hoelzl, F. Schliephake, T. Hummel, A. Chouker, K. Peter, and M. Thiel. 2006. Polymorphonuclear leukocyte dysfunction syndrome in patients with increasing sepsis severity. Shock. 26:254-261. doi:10.1097/01.shk.0000223131.64512.7a
12. Lindenmann, J., D.C. Burke, and A. Isaacs. 1957. Studies on the production, mode of action and properties of interferon. Br. J. Exp. Pathol. 38:551-562.
13. Mahieu, T., J.M. Park, H. Revets, B. Pasche, A. Lengeling, J. Staelens, A. Wullaert, I. Vanlaere, T. Hochepied, F. van Roy, et al. 2006. The wildderived inbred mouse strain SPRET/Ei is resistant to LPS and defective in IFN-beta production. Proc. Natl. Acad. Sci. USA. 103:2292-2297. doi:10.1073/pnas.0510874103
14. Maier, S., T. Traeger, M. Entleutner, A. Westerholt, B. Kleist, N. Hüser, B. Holzmann, A. Stier, K. Pfeffer, and C.D. Heidecke. 2004. Cecal ligation and puncture versus colon ascendens stent peritonitis: two distinct animal models for polymicrobial sepsis. Shock. 21:505-511. doi:10.1097/01.shk.0000126906.52367.dd
15. Mancuso, G., A. Midiri, C. Beninati, C. Biondo, R. Galbo, S. Akira, P. Henneke, D. Golenbock, and G. Teti. 2004. Dual role of TLR2 and myeloid differentiation factor 88 in a mouse model of invasive group B streptococcal disease. J. Immunol. 172:6324-6329.
16. Mancuso, G., A. Midiri, C. Biondo, C. Beninati, S. Zummo, R. Galbo, F. Tomasello, M. Gambuzza, G. Macrì, A. Ruggeri, et al. 2007. Type I IFN signaling is crucial for host resistance against different species of pathogenic bacteria. J. Immunol. 178:3126-3133.
17. Martin, F.J., M.I. Gomez, D.M. Wetzel, G. Memmi, M. O'Seaghdha, G. Soong, C. Schindler, and A. Prince. 2009. Staphylococcus aureus activates type I IFN signaling in mice and humans through the Xr repeated sequences of protein A. J. Clin. Invest. 119:1931-1939.
18. Müller, U., U. Steinhoff, L.F. Reis, S. Hemmi, J. Pavlovic, R.M. Zinkernagel, and M. Aguet. 1994. Functional role of type I and type II interferons in antiviral defense. Science. 264:1918-1921. doi:10.1126/science.8009221
19. Ness, T.L., C.M. Hogaboam, R.M. Strieter, and S.L. Kunkel. 2003. Immunomodulatory role of CXCR2 during experimental septic peritonitis. J. Immunol. 171:3775-3784.
20. Ng, P.C., K. Li, T.F. Leung, R.P. Wong, G. Li, K.M. Chui, E. Wong, F.W. Cheng, and T.F. Fok. 2006. Early prediction of sepsis-induced disseminated intravascular coagulation with interleukin-10, interleukin-6, and RANTES in preterm infants. Clin. Chem. 52:1181-1189. doi:10.1373/clinchem.2005. 062075
21. O'Connell, R.M., S.K. Saha, S.A. Vaidya, K.W. Bruhn, G.A. Miranda, B. Zarnegar, A.K. Perry, B.O. Nguyen, T.F. Lane, T. Taniguchi, et al. 2004. Type I interferon production enhances susceptibility to Listeria monocytogenes infection. J. Exp. Med. 200:437-445. doi:10.1084/jem.20040712
22. Olszyna, D.P., J.M. Prins, P.E. Dekkers, E. De Jonge, P. Speelman, S.J. Van Deventer, and T. Van Der Poll. 1999. Sequential measurements of chemokines in urosepsis and experimental endotoxemia. J. Clin. Immunol. 19:399-405. doi:10.1023/A:1020554817047
23. Peck-Palmer, O.M., J. Unsinger, K.C. Chang, C.G. Davis, J.E. McDunn, and R.S. Hotchkiss. 2008. Deletion of MyD88 markedly attenuates sepsis-induced T and B lymphocyte apoptosis but worsens survival. J. Leukoc. Biol. 83:1009-1018. doi:10.1189/jlb.0807528
24. Rittirsch, D., M.A. Flierl, B.A. Nadeau, D.E. Day, M. Huber-Lang, C.R. Mackay, F.S. Zetoune, N.P. Gerard, K. Cianflone, J. Köhl, et al. 2008. Functional roles for C5a receptors in sepsis. Nat. Med. 14:551-557. doi:10.1038/nm1753
25. Rogy, M.A., S.M. Coyle, H.S. Oldenburg, C.S. Rock, P.S. Barie, K.J. Van Zee, C.G. Smith, L.L. Moldawer, and S.F. Lowry. 1994. Persistently elevated soluble tumor necrosis factor receptor and interleukin-1 receptor antagonist levels in critically ill patients. J. Am. Coll. Surg. 178:132-138.
26. Sadler, A.J., and B.R. Williams. 2008. Interferon-inducible antiviral effectors. Nat. Rev. Immunol. 8:559-568. doi:10.1038/nri2314
27. Scumpia, P.O., M.J. Delano, K.M. Kelly, K.A. O'Malley, P.A. Efron, P.F. McAuliffe, T. Brusko, R. Ungaro, T. Barker, J.L. Wynn, et al. 2006. Increased natural CD4+CD25+ regulatory T cells and their suppressor activity do not contribute to mortality in murine polymicrobial sepsis. J. Immunol. 177:7943-7949.
28. Scumpia, P.O., M.J. Delano, K.M. Kelly-Scumpia, J.S. Weinstein, J.L. Wynn, R.D. Winfield, C. Xia, C.S. Chung, A. Ayala, M.A. Atkinson, et al. 2007. Treatment with GITR agonistic antibody corrects adaptive immune dysfunction in sepsis. Blood. 110:3673-3681. doi:10.1182/blood-2007-04-087171
29. Taneja, R., A.P. Sharma, M.B. Hallett, G.P. Findlay, and M.R. Morris. 2008. Immature circulating neutrophils in sepsis have impaired phagocytosis and calcium signaling. Shock. 30:618-622. doi:10.1097/SHK.0b013e318173ef9c
30. Toshchakov, V., B.W. Jones, P.Y. Perera, K. Thomas, M.J. Cody, S. Zhang, B.R. Williams, J. Major, T.A. Hamilton, M.J. Fenton, and S.N. Vogel. 2002. TLR4, but not TLR2, mediates IFN-beta-induced STAT1alpha/beta-dependent gene expression in macrophages. Nat. Immunol. 3:392-398. doi:10.1038/ni774
31. Uematsu, S., and S. Akira. 2007. Toll-like receptors and type I interferons. J. Biol. Chem. 282:15319-15323. doi:10.1074/jbc.R700009200
32. Vasquez, R.E., and L. Soong. 2006. CXCL10/gamma interferon-inducible protein 10-mediated protection against Leishmania amazonensis infection in mice. Infect. Immun. 74:6769-6777. doi:10.1128/IAI.01073-06
33. Weighardt, H., S. Kaiser-Moore, R.M. Vabulas, C.J. Kirschning, H. Wagner, and B. Holzmann. 2002. Cutting edge: myeloid differentiation factor 88 deficiency improves resistance against sepsis caused by polymicrobial infection. J. Immunol. 169:2823-2827.
34. Weighardt, H., S. Kaiser-Moore, S. Schlautkötter, T. Rossmann-Bloeck, U. Schleicher, C. Bogdan, and B. Holzmann. 2006. Type I IFN modulates host defense and late hyperinflammation in septic peritonitis. J. Immunol. 177:5623-5630.
35. Zeng, X., T.A. Moore, M.W. Newstead, J.C. Deng, N.W. Lukacs, and T.J. Standiford. 2005. IP-10 mediates selective mononuclear cell accumulation and activation in response to intrapulmonary transgenic expression and during adenovirus-induced pulmonary inflammation. J. Interferon Cytokine Res. 25:103-112. doi:10.1089/jir.2005.25.103